Publications by authors named "A del Nero"
Article Synopsis
- - Hyperhemolysis syndrome (HHS) is a severe condition that leads to anemia by destroying both donor and patient red blood cells, primarily occurring after blood transfusions, and can have serious health consequences.
- - A team from Transfusion Medicine and Hematology developed a consensus protocol for diagnosing and managing HHS, which includes specific diagnostic criteria like recent transfusion history, hemoglobin drop, and laboratory signs of hemolysis.
- - The study emphasizes a detailed management strategy aimed at improving blood cell production while reducing the immune response to enhance patient outcomes based on current research and clinical practices.
Children and adults with sickle cell disease (SCD) have increases in morbidity and mortality with COVID-19 infections. The American Society of Hematology Research Collaborative Sickle Cell Disease Research Network performed a prospective COVID-19 vaccine study to assess antibody responses and analyze whether messenger RNA (mRNA) vaccination precipitated any adverse effects unique to individuals with SCD. Forty-one participants received 2 doses of the Pfizer-BioNTech vaccine and provided baseline blood samples before vaccination and 2 months after the initial vaccination for analysis of immunoglobulin G (IgG) reactivity against the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike protein.
View Article and Find Full Text PDFBackground: Although nitric oxide based therapeutics have been shown in preclinical models to reduce vaso-occlusive events and improve cardiovascular function, a clinical trial of a phosphodiesterase 5 inhibitor increased rates of admission to hospital for pain. We aimed to examine if riociguat, a direct stimulator of the nitric oxide receptor soluble guanylate cyclase, causes similar increases in vaso-occlusive events.
Methods: This was a phase 1-2, randomised, double blind, placebo-controlled trial.
Article Synopsis
- Sickle cell disease patients with a history of stroke are generally advised to maintain a hemoglobin S (HbS) level below 30% to prevent strokes, but a new chronic exchange protocol by UT Southwestern allows for a higher target of below 50% for low-risk patients.
- A retrospective study reviewed medical records of 49 patients over 10 years, finding that 33 maintained an average HbS level of 35.4% without any strokes or transient ischemic attacks linked to this higher target.
- The results suggest that relaxing the HbS target may provide a flexible treatment option for certain patients without increasing stroke risk, although further research is needed to confirm these findings.
Article Synopsis
- Hyperhemolysis syndrome (HHS) is a rare transfusion reaction that can occur in conditions like sickle cell disease, leading to a drop in hemoglobin levels after receiving red blood cell transfusions, along with signs of hemolysis.
- A reported case involved a 28-year-old male with sickle cell disease who experienced severe symptoms and a dramatic drop in hemoglobin after being transfused while infected with the omicron variant of SARS-CoV-2.
- The findings suggest that sickle cell patients with COVID-19 could be at an increased risk for HHS due to similar underlying mechanisms affecting both conditions.